News

Lilly, obesity and Superluminal

Eli Lilly signs $1.3 billion deal with Superluminal to use AI to make obesity medicines
Lilly will receive exclusive rights to develop and commercialize drug candidates discovered using Superluminal's AI-driven platform.
Lilly signs up to $1.3 billion deal with Superluminal to develop obesity medicines
(Reuters) -Superluminal Medicines said on Thursday it had signed a deal with U.S. drugmaker Eli Lilly worth up to $1.3 billion, granting Lilly access to its AI-driven platform to discover and develop obesity drugs.
Superluminal secures $1.3B pact with backer Lilly to develop cardiometabolic, obesity drugs
Having backed Superluminal Medicines’ series A last year, Eli Lilly has now signed a $1.3 billion pact with the G protein-coupled receptor biotech. | Having backed Superluminal Medicines’ series A last year,
Eli Lilly Strikes $1.3 Billion Deal With Superluminal To Develop AI-Driven Obesity Drugs
Eli Lilly and Co (NYSE: LLY) has entered into a $1.3 billion deal with Superluminal Medicines to develop small-molecule drugs through artificial intelligence (AI) to treat obesity and other cardiometabolic diseases.
Eli Lilly seeks more GPCR weight loss drugs in $1.3bn research deal
Eli Lilly will pay up to $1.3bn for Superluminal Medicines to discover and progress small-molecule therapeutics for G protein-coupled receptors (GPCR) targets within the cardiometabolic and obesity space.
Eli Lilly Keeps Obesity Pipeline Fresh With $1.3B Superluminal Partnership
The Boston-based AI/ML startup focuses on endocrine and cardiometabolic diseases and will use that expertise to generate new small molecule obesity medications for Lilly.
Superluminal joins a $1.3B deal with series A backer Lilly
Superluminal Medicines Inc. and Eli Lilly and Co. are collaborating in a deal to develop cardiometabolic disease and obesity therapies by aiming at undisclosed G protein-coupled receptor targets. The deal could bring Superluminal as much as $1.
Eli Lilly Inks Up To $1.3B Deal With Superluminal Medicines To Develop Obesity Drugs
Eli Lilly (LLY) has entered into a deal worth up to $1.3 billion with drug discovery company Superluminal Medicines to advance small molecule therapeutics relevant to cardiometabolic diseases and obesity, Superluminal said on Thursday.
Eli Lilly partners with AI healthtech Superluminal Medicines
Superluminal Medicines, a healthcare company integrating AI/ML, announced partnership with Eli Lilly (NYSE:LLY) to advance small molecule therapeutics targeting cardiometabolic diseases and obesity. Under the deal,
Lilly invests in Boston biotech for $1.3B obesity drug deal
The latest obesity bet from Eli Lilly and Co. involves a Boston biotech based out of the pharma giant’s new Fort Point R&D center.
Eli Lilly, Superluminal Medicines announce collaboration
Superluminal Medicines, a drug discovery company integrating AI/ML, protein dynamics, and structural biology announced a collaboration with Eli

Eli Lilly (LLY) Advances Cardiometabolic Therapeutics In US$1.3 Billion Collaboration With Superluminal

Eli Lilly (LLY) recently collaborated with Superluminal Medicines to advance therapeutics targeting cardiometabolic diseases, ...
The Pharma Letter4h

Lilly and Superluminal work on GPCR drugs for cardiometabolic diseases

Eli Lilly (NYSE: LLY) has entered into a collaboration with Boston-based Superluminal Medicines to develop small-molecule ...